Scotgold Resources Limited (AIM: SGZ), Scotland’s first commercial gold producer, announces an operational and corporate update f or its Cononish Gold and Silver Mine in Scotland (“Cononish”).
Scotgold Resources (AIM:SGZ) plans new gold exploration in Scottish Highlands
Scotgold Resources will raise £2.5 million to fund growth plans that include exploration in the Scottish Highlands.
Scotgold Resources (AIM:SGZ) Results of Capital Raise
Scotgold Resources Limited (“Scotgold” or the “Company”) (AIM: SGZ), the gold exploration and production company focused on Scotland , is pleased to announce that following the accelerated bookbuild which was
Hemogenyx Pharma Plc (AIM:HEMO) HEMO-CAR-T 3rd Process Qualification Run Completed
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its third Process Qualification (“PQ”) run of
Hemogenyx Pharma Plc (LON:HEMO) Single CBR Can Treat Multiple Viruses
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor (“CBR”) platform technology, designed to program immune cells to
Could Scotgold Resources be on the verge of a Scottish gold rush?
The stunningly beautiful Loch Lomond & The Trossachs National Park in Scotland is a must-see. It is located at the base of the Highlands in the southwest.
Hemogenyx Pharma Plc Update With The Appointment of Medical Director
One of America’s Top Bone Marrow Transplant and Oncology Doctors Joins Hemogenyx Pharmaceuticals as Medical Director
Hemogenyx Pharma Plc (AIM:HEMO) CBR Update
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has achieved proof of concept (“POC”) for its
Hemogenyx Pharma Plc (AIM: HEMO) HEMO-CAR-T pre-IND Meeting Request
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, has received notification from the Food and Drugs Administration (“FDA”) that the proposed pre-Investigational
Hemogenyx Pharma Plc (HEMO.L) Hemo-CAR-T partnership with WuXi ATU
Partnership with WuXi Advanced Therapies to manufacture lentiviral vectors for phase I trial of cutting edge HEMO-CAR-T programme
Hemogenyx Pharma Plc (HEMO.L) HEMO-CAR-T pre-IND Meeting Request
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases.